The α7 nAChR subtype presents a potential approach for treating AD due to its high expression in cognitive function-related brain areas and interaction with Aβ.550,551 Selective positive allosteric modulators (PAMs) targeting the α7 nAChR subtype, such as compound 52, slowed the decline of episodic/working memory in amnesia mouse models. This evidence concerns the gene CHRNA7 and amnesia.